885068-00-8

Basic information

• Product Name: 2-(3-BROMOPHENYL)-2-METHYLPROPANOIC ACID
• Synonyms: 2-(3-BROMOPHENYL)-2-METHYLPROPANOIC ACID;2-(3-Boronophenyl)-2-Methylpropanoic acid;3-Borono-a,a-diMethyl-benzeneacetic acid
• CAS NO: 885068-00-8
• Molecular Formula: C₁₀H₁₃BO₄
• Molecular Weight: 208.02
• Mol File: 885068-00-8.mol

Chemical Properties

• Boiling Point: 413.9±47.0 °C(Predicted)
• Appearance: /
• Density: 1.24±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 4.41±0.10(Predicted)
• CAS DataBase Reference: 2-(3-BROMOPHENYL)-2-METHYLPROPANOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-BROMOPHENYL)-2-METHYLPROPANOIC ACID(885068-00-8)
• EPA Substance Registry System: 2-(3-BROMOPHENYL)-2-METHYLPROPANOIC ACID(885068-00-8)

Safety Data

• Hazardous Substances Data: 885068-00-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
2-(3-BROMOPHENYL)-2-METHYLPROPANOIC ACID is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the creation of new drug molecules with potential therapeutic effects.
Used in Organic Compounds Synthesis:
In the field of organic chemistry, 2-(3-BROMOPHENYL)-2-METHYLPROPANOIC ACID serves as a valuable building block for the synthesis of a wide range of organic compounds. Its presence in these compounds can impart specific properties and functionalities, making it a versatile component in organic synthesis.
Used in Medicinal Chemistry and Drug Development:
Due to its structural properties, 2-(3-BROMOPHENYL)-2-METHYLPROPANOIC ACID holds promise in medicinal chemistry and drug development. Researchers can utilize this compound to design and develop new drugs with improved efficacy and selectivity for various therapeutic targets.
Used in Chemical Research:
2-(3-BROMOPHENYL)-2-METHYLPROPANOIC ACID is also employed in chemical research to study its reactivity, stability, and potential interactions with other molecules. This knowledge can contribute to the advancement of chemical science and the development of new applications for this compound.
Safety Considerations:
It is important to handle 2-(3-BROMOPHENYL)-2-METHYLPROPANOIC ACID with caution, as it may pose health risks if not properly managed. Adequate safety measures, such as wearing protective gear and following proper disposal procedures, should be implemented to minimize potential hazards associated with this chemical compound.

Upstream product

• 81606-47-5 2-(3-bromophenyl)-2-methylpropanoic acid 
• 688-74-4 boric acid tributyl ester 

Downstream Products

• 885066-67-1 2-(3-{6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl}-phenyl)-2-methyl-propionic acid 
• 885068-57-5 C₂₄H₂₃N₃O₃S 
• 1098269-51-2 C₁₅H₁₅ClN₂O₃ 

Relevant articles and documents

DIHYDROGEN PHOSPHATE SALT OF A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST

The present invention is directed to dihydrogen phosphate salt 2-(3-{6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl}-phenyl)-2-methyl-propionic acid of Formula (III), a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of Formula (III), and a pharmaceutically acceptable carrier; and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like, by administering to said patient a pharmaceutically effective amount of the compound of Formula (III).

A COMBINATION OF NIACIN AND A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST

The present invention is directed to a pharmaceutical composition comprising Niacin or a pharmaceutically acceptable salt, solvate or N-oxide thereof, or a nicotinic acid receptor agonist, and a compound of formula (I) as defined herein, or an N-oxide thereof, or an ester prodrug thereof, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and its use for treating atherosclerosis, dyslipidemia, diabetes or a related condition while reducing substantial flushing.

2,6-SUBSTITUTED-4-MONOSUBSTITUTED AMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS

The present invention is directed to a compound of formula (I) wherein R1 and R2 are as defined herein, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, a pharmaceutically acceptable prodrug thereof, or a pharmaceutically acceptable salt, hydrate or solvate of the prodrug, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds of the invention in admixture with a pharmaceutically acceptable carrier, a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which are generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound of the invention.

2, 6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIDIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS

The present invention is directed a compound of Formula (I) as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, discorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (I).